Vinci Pharmaceuticals Raises $8M Series A Led by Dynagrow Capital

Vinci Pharmaceuticals Closes $8M Series A

Vinci Pharmaceuticals, a specialty ophthalmic pharmaceutical company based in Avon-by-the-Sea, New Jersey, has raised an $8 million Series A round. The financing was led by Dynagrow Capital, with participation from MintPharma Capital.

What the Company Does

Vinci Pharmaceuticals is focused on developing first-, best- and only-in-class therapies for diseases of the retina. The company's work centers on addressing a well-known limitation in retinal care: the burden of repeated intraocular injections.

Its proprietary EPIPLANT platform is an episcleral, needle-free sustained-release drug delivery implant designed to overcome those limitations. The lead product candidate is VCI-002.

Technology Origins

The EPIPLANT technology was developed in the laboratory of Karl Csaky, MD, PhD, and licensed from the Retina Foundation of the Southwest. That foundation-backed origin gives the program a defined scientific lineage as it moves toward clinical evaluation.

Clinical Timeline

According to the company, Vinci Pharmaceuticals is preparing a first-in-human Phase 1/2a study in 2027. The Series A capital arrives ahead of that planned milestone.

Round Summary

• Company: Vinci Pharmaceuticals
• Round: Series A
• Amount: $8,000,000 USD
• Lead investor: Dynagrow Capital
• Additional investors: MintPharma Capital
• Sector: Specialty ophthalmic pharmaceuticals / retinal disease therapies
• Headquarters: Avon-by-the-Sea, New Jersey

Why It Matters

Retinal disease treatment has long depended on frequent intraocular injections, a delivery model that places recurring burden on patients and providers alike. Vinci Pharmaceuticals is positioning EPIPLANT — and specifically VCI-002 — as a needle-free, sustained-release alternative delivered episclerally. If the approach performs in the clinic, it would target a structural pain point in ophthalmic care rather than an incremental improvement.

The company's stated pipeline ambition spans first-, best- and only-in-class therapies, with the EPIPLANT platform serving as the delivery foundation.

What Comes Next

The near-term focus is the planned first-in-human Phase 1/2a study in 2027. For a company at this stage, the Series A provides runway to advance VCI-002 toward that readout while continuing development of the broader EPIPLANT platform.

For observers tracking ophthalmic drug delivery, Vinci Pharmaceuticals now has both a licensed technology base and fresh institutional backing as it approaches its first clinical test.